IDH1 and central nervous system cancer: In a phase 1b/2 trial enrolling 26 adult patients with relapsed/refractory WHO Grade 3 and 4 IDH1 R132X-mutant glioma, olutasidenib resulted in a disease control rate (objective response plus stable disease) of 48% (99).